Tyche Wealth Partners LLC Invests $751,000 in Axon Enterprise, Inc. (NASDAQ:AXON)

Tyche Wealth Partners LLC bought a new position in Axon Enterprise, Inc. (NASDAQ:AXON) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 2,907 shares of the biotechnology company’s stock, valued at approximately $751,000.

Several other large investors have also recently modified their holdings of the business. BlackRock Inc. grew its stake in Axon Enterprise by 11.7% during the first quarter. BlackRock Inc. now owns 8,329,479 shares of the biotechnology company’s stock valued at $1,872,883,000 after acquiring an additional 870,481 shares in the last quarter. Capital International Investors grew its stake in Axon Enterprise by 605.2% during the first quarter. Capital International Investors now owns 2,660,634 shares of the biotechnology company’s stock valued at $366,449,000 after acquiring an additional 2,283,343 shares in the last quarter. Sands Capital Management LLC grew its stake in Axon Enterprise by 31.1% during the third quarter. Sands Capital Management LLC now owns 2,612,305 shares of the biotechnology company’s stock valued at $519,823,000 after acquiring an additional 619,179 shares in the last quarter. State Street Corp grew its stake in Axon Enterprise by 12.6% during the first quarter. State Street Corp now owns 2,377,095 shares of the biotechnology company’s stock valued at $534,484,000 after acquiring an additional 266,465 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in Axon Enterprise by 3.3% during the third quarter. Wellington Management Group LLP now owns 1,956,022 shares of the biotechnology company’s stock valued at $389,229,000 after acquiring an additional 62,324 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on AXON. Morgan Stanley boosted their price objective on shares of Axon Enterprise from $250.00 to $285.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. boosted their price target on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “overweight” rating in a research note on Thursday, April 11th. TheStreet cut shares of Axon Enterprise from a “b” rating to a “c+” rating in a research note on Tuesday, February 27th. The Goldman Sachs Group boosted their price target on shares of Axon Enterprise from $297.00 to $339.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Finally, StockNews.com cut shares of Axon Enterprise from a “buy” rating to a “hold” rating in a research note on Thursday, March 14th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average target price of $312.64.

Axon Enterprise Trading Down 0.3 %

Axon Enterprise stock traded down $1.01 during mid-day trading on Wednesday, reaching $299.30. 18,259 shares of the company traded hands, compared to its average volume of 459,491. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.00 and a quick ratio of 2.66. The firm’s 50 day moving average price is $299.16 and its 200 day moving average price is $256.71. The firm has a market capitalization of $22.59 billion, a price-to-earnings ratio of 130.57 and a beta of 0.93. Axon Enterprise, Inc. has a 52-week low of $175.37 and a 52-week high of $329.87.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.29. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. The firm had revenue of $432.14 million for the quarter, compared to the consensus estimate of $418.97 million. On average, analysts anticipate that Axon Enterprise, Inc. will post 2.43 earnings per share for the current fiscal year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.